Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Feb 22, 2019 7:43pm
136 Views
Post# 29402652

RE:Lend my share to Fidelity?

RE:Lend my share to Fidelity?https://www.marketwatch.com/story/how-small-investors-lend-shares-to-hard-pressed-short-sellers

There is an old article addressing the issue. I’d like to see SPCEO comment.

If Fidelity is offering you 5%, they are then charging someone north of 7% to borrow thr shares. Someone wants to have short exposure on TH.

If you’re a long term investor, you should likely take the 5%.

It perplexes me why some entity would want to short at this point but there are always two ways to look at a stock.

bfw




longterm56 wrote:
Hi all -

I need some input.  I got this email from Fidelity (below) today asking me to lend them my THERF shares.  Is this a good thing?  I remember reading some time ago that brokerages borrow shares to short them.  Is that the only purpose?  If so, why would Fidelity want to do this now?

Thanks for any info -

   -LT

Fidelity Investments - Lending Opportunity - (THERF) Theratechnologies Inc

<joe> your financial consultant in the <my city> branch asked me to make you aware of an opportunity that Fidelity makes available to qualifying clients.  Fidelity's Fully Paid Lending Program provides clients the opportunity to earn incremental income on their portfolio through the securities lending market.  The program allows Fidelity to borrow fully paid and excess margin securities from your account.  In return, you receive collateral which is held at a custodial bank and marked to market daily.  In addition, you receive a monthly lending fee which is automatically credited to your Fidelity Account.  You maintain full economic ownership of securities on loan and may sell the shares on loan at any time, including online.  You can also monitor your securities on loan in the same manner as the rest of your portfolio.  The duration of a loan is typically indefinite and may remain open until you or Fidelity wish to close it. 
 
Currently, the following positions and rates could apply (subject to change based on market conditions):
 
THERF – 5%


Bullboard Posts